The Facility connects a pool of demand to a pool of supply

Bold ideas and brilliant innovation for the worst global health crisis in 100 years

Participants

Pooled demand & financing
Consolidates buying power and provides participants access to a broad and actively-managed portfolio

The COVAX Facility

Manufacturers

Pooled supply
Provides manufacturers access to a massive, demand-assured market
Objectives of COVAX for 2021

To end the acute phase of the pandemic by end 2021

To deliver 2 billion doses by end 2021

To guarantee fair and equitable access to COVID-19 vaccines for all participants

To support the largest actively managed portfolio of vaccine candidates globally

To offer a compelling return on investment by delivering COVID-19 vaccines as quickly as possible

With supply contribution of vaccine manufacturers, COVAX will continue to support countries’ needs and ambitions to control the disease and reopen society in 2022 and beyond.
**COVAX Facility: 6 Key Metrics**

- **$10.9bn raised for COVAX AMC** ($10.1bn for vaccines and $0.8bn for delivery) against our 2021 target of $9.3bn
  - 117% of $9.3bn target

- **11 vaccine candidates with signed agreements** against our 2021 target of 10 candidates
  - 110% of 10 candidates target

- **1.43bn doses for delivery in 2021**, based on signed agreements, against our 2021 target of 2bn doses for delivery in 2021**, including an estimated 0.4bn doses for delivery in 2021 from dose-sharing
  - 71%

- **94% of COVAX participants** have received first shipment of doses against our June 2021 target of 100% of participants
  - 94%

- Of **587M doses allocated** 355M doses delivered to COVAX economies against our 2021 target of 2bn doses
  - 18%

- **3,627,627,096 people vaccinated** against COVID-19 with at least 1 dose from all vaccine sources
  - COVAX specific metric and target in progress

---

*Of the 153 of 163 active participants who have received an allocation. 31 of the 194 confirmed and eligible participants are not active—the 27 EU member states (represented by the European Commission who is active), 3 non-participating AMC eligible economies and 1 SFP who has left the Facility. 10 participants were not allocated doses due to opt-outs, voluntary delays and unmet financial commitments. **Volumes at risk due to constraints in manufacturing (production levels) and supply (export controls); Source: Supply Forecast - [https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20%20Forecast.pdf](https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20%20Forecast.pdf); Deliveries: # people vaccinated: [https://covid19.who.int/](https://covid19.who.int/)
22 of the 42 DCVM are manufacturing DS and/or DP against Covid-19 and/or are developing a new candidate, and continue to supply the other vaccines.

NB: DCVM contribute to ~50% of Covid-19 vaccine 2021 supply (in doses)

Legend
- R&D stage only
- DP – Other vaccines
- DP – Covid-19 & other vaccines
- DS+DP – Other vaccines
- DS+DP – Covid-19 & other vaccines
- DCVM with WHO PQ’d vaccines

Source: DCVMN website October 2021; WHO website September 2021; Linlebridge Covid-19 dashboard September 2021

* Includes Covid-19 vaccine candidates under development
Key Challenges Facing COVAX and Mitigation Plans

Focus on Manufacturing and Supply
### COVAX Facility global supply forecast – 2021 to 2022

By AMC-eligible and Self-Financing Participants

**PRELIMINARY AND SUBJECT TO ASSUMPTIONS**

#### COVAX Forecasted Supply under Most Likely Scenario,
Cumulative, M doses, 2021 and 2022

<table>
<thead>
<tr>
<th>Month</th>
<th>2021</th>
<th>2022</th>
<th>End-2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Feb</td>
<td>11</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Mar</td>
<td>20</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Apr</td>
<td>50</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>May</td>
<td>100</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Jun</td>
<td>220</td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>Jul</td>
<td>330</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>Aug</td>
<td>470</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Sep</td>
<td>700</td>
<td>170</td>
<td></td>
</tr>
<tr>
<td>Oct</td>
<td>1,000</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>Nov</td>
<td>1,425</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>Dec</td>
<td>1,865</td>
<td>170</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2,290</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2,660</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5,935</td>
<td></td>
</tr>
</tbody>
</table>

Potential volumes currently available, assuming all deals under negotiation are signed and all options are exercised, subject to funding availability.

Equivalent to 37% coverage in AMC91

Equivalent to 20% coverage in AMC91

Reflects COVAX doses released to date

#### CAVEATS

- **Contracts:** Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

- **Candidate attrition:** Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

- **Manufacturing:** In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

- **Delivery:** Timing shown in graphs is based on anticipated date of release by manufacturers. Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

- **Funding availability:** Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

- **Allocation:** These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

---

1. Forecasts are based on best available information from manufacturers and analysis from Gavi and UNICEF. Timing of available supply is based on anticipated date of release by manufacturer, at which point doses become available for delivery; as such, timing of delivery to countries will be lagged. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.

2. Final SFP volumes may be lower than forecasted due to opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.

3. “Dose donations” estimated based upon donor commitments to share new doses bilaterally with COVAX. The transfer of COVAX allocations from SFPs to AMC Participants are already included in the AMC Participant volumes.

Updated on 8 Sept 2021
COVAX supply forecast is not static and is being impacted by multiple headwinds

September forecast vs. July forecast
Evolution of total anticipated supply by manufacturer in 2021 (M doses)

Sources of net difference in supply:
- A mix of the below
- Delayed development and approval
- Export ban
- Delayed manufacturing ramp-up
- Pre-commitments to other markets
- Additional Supply
- Donations
COVAX Mitigation Plan
Dose donations to deliver ~400M doses before end of 2021

Donations by manufacturer to AMC to date

- Mfr 1: 85
- Mfr 2: 50
- Mfr 3: 30
- Mfr 4: 30

Dose donations should deliver 1,300M doses in 2021-22

- USA: 800
- EUROPE: 300+
- UK: 100
- Japan: 60
- Canada: 40
- etc…
Facilitate Manufacturing and Supply of COVID-19 Vaccine Doses

**Current situation & challenge**
Vaccine manufacturers and suppliers of key inputs are scaling up with an announced cumulative supply target of up to 12+ billion doses by the end of 2021 – at least three times the pre-COVID19 annual global supply for all vaccines.¹

Shortages in most critical input supplies have been identified by COVID-19 vaccine manufacturers as a rate limiting step

<table>
<thead>
<tr>
<th>Objectives</th>
<th>The COVAX Manufacturing Taskforce has developed an exchange concept to improve utilisation of these scarce supplies by</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Providing suppliers with a broad platform to (re-)allocate materials and capacity slots becoming available through further scaling or sudden shifts in demand</td>
</tr>
<tr>
<td></td>
<td>• Mobilising idle stock from vaccines and candidates that fail prior to gaining regulatory approval – as well as from those that might scale down their production in the future</td>
</tr>
<tr>
<td></td>
<td>• Mobilising potential surplus stock from manufacturers with non-vaccination activities</td>
</tr>
</tbody>
</table>

| Goals | To facilitate production of COVID-19 vaccine doses, promoting equitable access to vaccines in the context of COVAX |

---

¹ WHO Global Vaccine Market Report 2019, 2020
COVAX Mitigation Plan

Manufacturing Taskforce Short Term Effort

(2) Facilitate Free Flow of Goods through WTO-CEPI partnership

Activities have focused on actions from the Jun’21 WTO Summit
- Supply chain transparency, customs procedures and tariffs
- Supporting the Harmonized System (HS) coding initiative by providing intel on Marketplace supply chain challenges, indicative list of vaccine inputs, and trade-related bottlenecks
- Ministerial Conference in November 2021

Immediate COVID-19 need
- Selective modification of customs procedures to shorten time across borders
  - Requires customs officials to identify COVID-19 related products
  - May require accelerating HS code modifications for expedited status
- Supply chain adjustments
  - Supply chain transparency to enable clearer demand signals
  - Temporarily reducing manufacturer’s safety stocks
Strategic Priorities for 2022 and beyond
COVAX Pillar 2021 - 2022 strategic priorities – ambition levels

Accelerate the end of the acute phase of the COVID-19 pandemic by the end of 2021
Support countries’ needs and ambitions to control the disease and reopen society in 2022 and beyond

Robust foundation for countries’ vaccination coverage ambitions

Continue to build a robust foundation for countries’ vaccination coverage ambitions by pooling demand, supply & resources, complemented by other procurement mechanisms

Actively managed portfolio of effective, affordable & scalable vaccines

Support and help accelerate a portfolio and pipeline of effective, affordable and scalable vaccines

Advancing equitable access & fair allocation

Advance equitable access and fair allocation evolving the model to reflect absorption and country preferences and ambitions,

Increased support and innovative solutions to in-country delivery for AMC92

Offer increased support and innovative solutions to in-country delivery for AMC92.

Source: 2022 and beyond COVAX Pillar Strategy memo
COVAX Manufacturing Taskforce Long-Term Effort

Improve long-term LMIC health security via two key objectives and enablers

**Objective 1**
Expand capabilities of existing manufacturers in LMICs

**Objective 2**
Establish sustainable capacity in regions with no significant capacity

**Enablers**
Identify & implement innovations and develop normative frameworks
COVAX calls upon the world and its partners to help deliver on its goals and strategic priorities for 2022 and beyond

- **a** Support COVAX’s goal of increasing its contribution to global supply through funds, dose donations or cost-sharing

- **b** Ask manufacturers and governments to prioritise the delivery of COVAX doses, on or ahead of agreed timelines, and the global provisioning of prime doses before that of boosters

- **c** Ensure existing and emerging evidence gaps are tackled equitably and systematically to support health policy development in AMC92

- **d** Increase data and information sharing, improving transparency on the access to and uptake of COVID-19 vaccines globally, drawing on all sources of supply

- **e** Ensure all possible efforts are made to prepare, fund, and execute the major delivery programs required to absorb this volume

- **f** Foster highly active collaboration between all mechanisms focused on equity in support of the needs of AMC participants.

Source: 2022 and beyond COVAX Pillar Strategy memo

October 19, 2021
Thank you